2024 is shaping up to be a vitally important year for the future of allogeneic cell therapies. With exciting clinical data readouts expected in the coming months and the cell therapy community recognizing autoimmune indications as the promising new cornerstone of research – the tide is shifting for off-the-shelf therapies.

Leaders from Caribou Biosciences, Atara Biotherapeutics, Adicet Bio and many more spoke at the 6th Annual Allogeneic Cell Therapies Summit to share their exciting pipeline developments and best practices when it comes to novel modifications for allogeneic cells, platforms to allow upscaling of manufacturing and to understanding which new disease indications will benefit from your universal cell products.

This was the golden opportunity to connect with other cell therapy leaders to accelerate your allogeneic pipelines in 2024 and beyond!